For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...

Company Overview - Amgen is one of the largest biotech companies globally, focusing on oncology/hematology, cardiovascular disease, inflammation, bone health, and rare diseases markets [11] - The company has developed significant drugs such as Epogen and Neupogen, and launched next-generation products like Aranesp and Neulasta [11] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition [11] Financial Performance - Amgen has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a solid position in the market [12] - The company has a Value Style Score of B, supported by a forward P/E ratio of 15.68, which is attractive for value investors [12] - For fiscal 2025, three analysts have revised their earnings estimates upwards, with the Zacks Consensus Estimate increasing to $21.28 per share [12] - Amgen has an average earnings surprise of +12.7%, suggesting a positive trend in earnings performance [12] Investment Considerations - With a strong Zacks Rank and favorable Value and VGM Style Scores, Amgen is recommended for investors' consideration [13]

Group 1 - Advantest Corp. (ATEYY) has shown strong year-to-date performance, gaining approximately 50.4%, outperforming the average gain of 30.3% in the Computer and Technology sector [4] - The Zacks Rank for Advantest Corp. is currently 1 (Strong Buy), indicating a positive earnings outlook as the consensus estimate for full-year earnings has increased by 12.2% over the past three months [3] - Advantest Corp. belongs to the Electronics - Measuring Instruments industry, which has an average gain of 43.5% this year, further indicating that ATEYY is performing well compared to its industry peers [5] Group 2 - The Computer and Technology sector includes 611 individual stocks and holds a Zacks Sector Rank of 3, reflecting the performance of various sector groups [2] - SK Telecom (SKM), another stock in the Computer and Technology sector, has also outperformed the sector with a year-to-date return of 32.5% and a Zacks Rank of 1 (Strong Buy) [4][5] - The Wireless Non-US industry, to which SK Telecom belongs, has moved up by 54.3% year to date, indicating strong performance within that specific industry [6]

Company Overview - Chubb Limited, formerly known as ACE Limited, is one of the world's largest providers of property and casualty (P&C) insurance and reinsurance, with a market capitalization of $86 billion [12] - The company has diversified through acquisitions into various specialty lines, including marine, medical risk, excess property, environmental, and terrorism insurance, and operates in 54 countries and territories [12] Investment Ratings - Chubb has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a solid position but not a strong buy [13] - The Value Style Score is also rated B, supported by attractive valuation metrics such as a forward P/E ratio of 11.62, which may appeal to value investors [13] Earnings Estimates - In the last 60 days, five analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.39 to $24.10 per share [13] - Chubb has an average earnings surprise of +13.4%, suggesting a positive trend in earnings performance [13] Investment Consideration - With a solid Zacks Rank and top-tier Value and VGM Style Scores, Chubb is recommended to be on investors' short lists for potential investment opportunities [14]

Company Overview - ResMed (RMD) is a notable stock within the Medical sector, which consists of 929 individual stocks and ranks 10 in the Zacks Sector Rank [2] - ResMed currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Analysis - Year-to-date, ResMed has achieved a return of approximately 7%, outperforming the average gain of 6.3% for the Medical sector [4] - In comparison, Compass Therapeutics, Inc. (CMPX) has returned 14.7% year-to-date, also outperforming the sector [4] - ResMed is part of the Medical - Products industry, which includes 82 companies and currently ranks 155 in the Zacks Industry Rank; this industry has seen an average loss of 5.6% year-to-date, further highlighting ResMed's strong performance [5] Industry Context - The Medical - Biomedical and Genetics industry, which includes Compass Therapeutics, consists of 450 stocks and is currently ranked 90, with a year-to-date increase of 21.1% [6] - Investors are encouraged to monitor both ResMed and Compass Therapeutics for their continued strong performance in the Medical sector [6]

Company Overview - Corporacion America Airports S.A. (CAAP) is part of the Transportation group, which includes 115 companies and is currently ranked 9 in the Zacks Sector Rank [2] - CAAP has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook based on earnings estimates and revisions [3] Performance Analysis - Over the past three months, the Zacks Consensus Estimate for CAAP's full-year earnings has increased by 0.9%, reflecting improved analyst sentiment [4] - CAAP has returned approximately 12% year-to-date, outperforming the average gain of 4.1% in the Transportation group [4] - In the Transportation - Airline industry, which includes 24 companies, CAAP is slightly underperforming with a year-to-date gain compared to the industry's average of 15.1% [6] Comparative Analysis - Freightcar America (RAIL), another stock in the Transportation sector, has a year-to-date return of 4.3% and a Zacks Rank of 2 (Buy) [5] - The Transportation - Equipment and Leasing industry, to which Freightcar America belongs, has gained 18.3% year-to-date, indicating stronger performance compared to CAAP's industry [7]

Core Viewpoint - EverQuote (EVER) is experiencing significant selling pressure, with a 15.6% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better-than-previously predicted earnings [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - EVER's current RSI reading of 28.98 suggests that the heavy selling may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for EVER will improve, leading to a 1.5% increase in the consensus EPS estimate over the last 30 days, which often correlates with near-term price appreciation [7]. - EVER holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

分组1 - West Bancorp reported quarterly earnings of $0.61 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and up from $0.42 per share a year ago, representing an earnings surprise of +7.02% [1] - The company achieved revenues of $27.27 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.53%, compared to year-ago revenues of $22.02 million [2] - West Bancorp has consistently surpassed consensus EPS estimates for the last four quarters [2] 分组2 - The stock has added about 0.6% since the beginning of the year, while the S&P 500 has gained 1.9% [3] - The current consensus EPS estimate for the coming quarter is $0.55 on revenues of $26.5 million, and for the current fiscal year, it is $2.40 on revenues of $112.2 million [7] - The Financial - Savings and Loan industry, to which West Bancorp belongs, is currently in the top 15% of Zacks industries, indicating a favorable outlook [8]

Key Takeaways FN will report fiscal Q2 results with revenues expected between $1.05-$1.10 billion and EPS of $3.15-$3.30.FN's telecom and DCI businesses are driving growth, supported by strong demand and rising HPC adoption.FN's results may be constrained by flat automotive revenue and margin pressure from FX headwinds.Fabrinet (FN) is slated to release second-quarter fiscal 2026 results on Feb. 2.For the fiscal second quarter, revenues are expected in the range of $1.05-$1.10 billion. Non-GAAP earnings per ...

Core Viewpoint - Cencora (COR) is expected to report strong first-quarter fiscal 2026 results, with positive revenue and earnings growth driven by pharmaceutical utilization trends and specialty-focused assets [1][3][7] Group 1: Financial Estimates - The Zacks Consensus Estimate for revenues is $85.97 billion, reflecting a 5.5% increase from the prior-year quarter [2] - The consensus estimate for earnings is $4.05 per share, indicating an 8.6% improvement from the previous year's figure [2] Group 2: Performance Drivers - Cencora's performance is anticipated to be supported by strong drug volumes and the U.S. Healthcare Solutions segment, which is expected to be the primary earnings driver [3][5][7] - The integration of Retina Consultants of America (RCA) is likely to contribute positively to sales and margins [3][4] Group 3: Segment Analysis - The U.S. Healthcare Solutions segment is projected to generate sales of $76.72 billion, benefiting from specialty distribution and MSO platforms [6][7] - The International Healthcare Solutions segment is expected to maintain growth, with sales estimated at $7.45 billion, supported by stable trends in Europe and World Courier momentum [6][8] Group 4: Margin and Growth Outlook - Margin performance is expected to remain favorable due to mix benefits from specialty distribution and MSO-related services, despite higher interest expenses from acquisition financing [4][5] - Specialty utilization, particularly in Part B drugs, is anticipated to support above-trend operating income growth [5]